Preliminary clinical efficacy of transcatheter aortic valve replacement for severe aortic stenosis
-
摘要: 目的:总结经导管主动脉瓣置换术(TAVR)治疗重度主动脉瓣狭窄(AS)的初步临床经验。方法:纳入2018年10月-2019年10月于我院接受TAVR治疗的重度AS患者21例,分析其临床资料、手术效果及并发症情况。结果:患者平均年龄(73.71±8.91)岁,男9例,女12例。手术成功率为100%,术后即刻主动脉瓣跨瓣压差较术前明显下降[(7.71±5.32) mmHg∶(100.19±30.13) mmHg,1 mmHg=0.133 kPa,P<0.01]。术中联合ECMO支持1例,联合经导管二尖瓣球囊扩张1例,联合经皮冠状动脉支架植入术(PCI)1例,瓣中瓣植入2例。术后消化道出血1例,永久性起搏器植入2例,发热2例,急性脑梗死1例,轻度瓣周漏11例,股动脉穿刺点处假性动脉瘤1例,临时起搏器置入处皮下血肿1例,死亡1例。术后30 d患者症状及心脏超声指标均改善。结论:TAVR治疗外科手术禁忌或高危重度主动脉瓣狭窄相对安全、有效。Abstract: Objective:To summarize the preliminary experience of transcatheter aortic valve replacement(TAVR) in the treatment of severe aortic stenosis(AS).Method:Twenty-one patients with severe AS who underwent TAVR in the First Affiliated Hospital of Zhengzhou University from October 2018 to October 2019 were enrolled.The clinical data,surgical results,and complications were analyzed.Result:The mean age of patients(73.71±8.91) years,9 males,12 females.The success rate of surgery was 100% and the aortic valve transvalvular pressure difference decreased immediately after surgery compared with preoperative [(7.71±5.32) mmHg ∶(100.19±30.13) mmHg,P<0.01].There were 1 case of intraoperative combined with ECMO support,1 case of combined with transcatheter mitral balloon dilatation,1 case combined with coronary artery stenting(PCI),2 cases of anterior valve implantation,1 case of postoperative gastrointestinal bleeding,2 cases of permanent pacemaker implantation,2 cases of fever,1 case of acute cerebral infarction,11 cases of mild perivalvular leakage,1 case of pseudoaneurysm at the femoral artery puncture point,1 case of subcutaneous hematoma with temporary pacemaker placement,and 1 case of death.The symptoms and cardiac ultrasound index improved after 30 days of follow-up.Conclusion:TAVR is safe and effective in the treatment of surgical contraindications or high-risk severe aortic stenosis.
-
[1] 谷喆,张倩,吴永健.主动脉瓣重度狭窄患者左室肥厚机制和临床意义[J].中国循证心血管医学杂志,2017,9(5):636-637.
[2] Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival[J]. Circulation,1982,66(5):1105-1110.
[3] 王圣,任培军,陈现杰,等.不同治疗方式对高龄钙化性主动脉瓣重度狭窄患者预后的影响[J].临床心血管病杂志,2019,35(6):540-543.
[4] Baumgartner H, Falk V, Bax JJ, et al.2017 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2017,38(36):2739-2791.
[5] 李忠城,苏建,李菊香.经导管主动脉瓣置换术对于外科低危主动脉瓣狭窄患者有效性和安全性的 Meta 分析[J].临床心血管病杂志,2019,35(9):835-841.
[7] Siontis GC, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs surgical aortic valve replacement for treatment of severe aortic stenosis:a meta-analysis of randomized trials[J]. Eur Heart J,2016,37(47):3503-3512.
[8] 葛均波,周达新,潘文志,等.经导管主动脉瓣置入术的初步经验[J].中华心血管病杂志,2011,39(11):989-992.
[9] Kaul S. Transcatheter aortic-valve replacement with a self-expanding prosthesis[J]. N Engl J Med,2014,371(10):967.
[10] Popmaj JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery[J]. J Am Coll Cardiol,2014,63(19):1972-1981.
[11] Ozier D, Zivkovic N, Elbaz-Greener G, et al. Timing of conduction abnormalities leading to permanent pacemaker insertion after transcatheter aortic valve implantation-A Single Centre-Review[J]. Can J Cardiol,2017,33(12):1660-1667.
[12] 杨力凡,潘文志,张晓春,等.单中心100例经导管主动脉瓣置换(TAVR)结果分析[J].复旦学报,2019,46(2):238-242.
[13] Tang GHL, Kaneko T. Assessing implant depth using aortography in transcatheter aortic valve replacement:what you see may not be what you get[J]. JACC Cardiovasc Interv,2018,11(2):129-132.
[14] Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3[J]. JACC Cardiovasc Interv,2016,9(21):2200-2209.
[15] Kapadia SR, Huded CP, Kodali SK, et al. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER Trial [J]. J Am Coll Cardiol,2018,72(20):2415-2426.
[16] Werner N, Zeymer U, Schneider S, et al. Incidence and clinical impact of stroke complicating transcatheter aortic valve implantation:results from the German TAVI registry[J]. Catheter Cardiovasc Interv,2016,88(4):644-653.
[17] Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2017,69(4):367-377.
[18] Giustino G, Sorrentino S, Mehran R, et al. Cerebral embolic protection during TAVR:a clinical event meta-analysis[J]. J Am Coll Cardiol,2017,69(4):465-466.
[19] Kapadia SR, Leon MB, Makkar RR, et al.5- year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1):a randomised controlled trial[J]. Lancet,2015,385(9986):2485-2491.
[20] Pibarot P, Hahn RT, Weissman NJ, et al. Association of paravalvular regurgitation with 1- year outcomes after transcatheter aortic Valve Replacement With the SAPIEN 3 Valve[J]. JAMA Cardiol,2017,2(11):1208-1216.
[21] Conte JV, Hermiller J Jr, Resar JR, et al. Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement[J]. Semin Thorac Cardiolvasc Surg,2017,29(3):321-330.
[22] 苏文华,霍倩,赵燕,等.经导管主动脉瓣植入术治疗二叶式主动脉瓣重度狭窄有效性及安全性的 Meta 分析[J].临床心血管病杂志,2017,33(6):564-569.
计量
- 文章访问数: 183
- PDF下载数: 70
- 施引文献: 0